The Institute for Clinical and Economic Review (ICER) has released their revised evidence report for Eli Lilly’s new type 2 diabetes drug tirzepatide. The drug is intended as an adjunct therapy for metformin and is more effective than injectable semaglutide, another adjunct therapy. A virtual public meeting on January 20th hosted by New England CEPAC will give an opportunity for independent experts to review the evidence report.
According to an ICER press release, “Tirzepatide is not yet approved by the FDA, and its manufacturers have not yet announced what the treatment’s US price would be if approved. ICER’s health-benefit price benchmark (HBPB) range for tirzepatide is between $5,500 – $5,700 per year. This range factors in assumptions about long-term cardiovascular benefits that have not been directly demonstrated yet in clinical trials.”
Click here to read the entire report.
(Source: ICER, January 6th, 2022)